Conshohocken’s Cencora is strengthening its footprint in specialty medicine with a new agreement, the company announced in a press release.
Cencora will acquire TPG’s equity interest in OneOncology, a physician-led national platform supporting independent oncology practices.
The move builds on Cencora’s existing partnership with OneOncology and signals a deeper investment in helping independent cancer specialists remain autonomous while gaining access to expanded resources. OneOncology has grown rapidly in recent years, attracting practices nationwide by combining local, physician-led care with shared services, technology, and clinical innovation.
Cencora leaders say the expanded investment aligns with the company’s pharmaceutical-centric strategy and its broader focus on advancing specialty care. By integrating OneOncology more fully into its portfolio, Cencora aims to enhance research capabilities, expand access to clinical trials, and strengthen technology platforms that support physicians and patients alike.
For OneOncology, the agreement marks the next phase following years of growth backed by TPG. Company leaders say continued collaboration with Cencora will help practices navigate an increasingly complex cancer-care landscape while keeping care rooted in local communities.
Cencora has steadily expanded its healthcare services platform through targeted acquisitions, reinforcing the region’s role as a hub for life sciences and medical innovation.
To learn more about the transaction and its impact on cancer care, visit PR Newswire.
